MGL-3196 is a highly selective and orally active thyroid hormone receptor β (THRβ) agonist with an EC50 value of 0.21μM[1]. THRβ is a nuclear receptor that plays a key role in regulating metabolism, growth, and development by binding to thyroid hormones and modulating gene expression[2]. MGL-3196 can be used for the study of nonalcoholic steatohepatitis and cardiovascular diseases[3][4].
In vitro, treatment of HEK-1B1 cells with MGL-3196 (6μM; 48h) significantly induced the expression of THRβ target genes like KLF9 and PCK1 and enhanced mitochondrial respiration[5].
In vivo, MGL-3196 (3mg/kg/day; gavage; 8 weeks) reduced liver weight, circulating triglycerides and total cholesterol, and improved histological signs of steatosis and fibrosis in SPF mice fed a MASH diet[6]. MGL-3196 (1mg/kg/day; orally; 8 weeks) significantly reduced liver weight, improved histological steatosis and lobular inflammation scores, and lowered plasma cholesterol and alanine transaminase (ALT) levels in a mouse model of fatty liver disease induced by the GAN diet[7].
References:
[1] Kelly MJ, Pietranico-Cole S, Larigan JD, et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia. J Med Chem. 2014;57(10):3912-3923.
[2] Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014;94(2):355-382.
[3] Keam SJ. Resmetirom: First Approval. Drugs. 2024;84(6):729-735.
[4] Zisis M, Chondrogianni ME, Androutsakos T, et al. Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment. Biomolecules. 2025;15(3):324.
[5] Hones GS, Sivakumar RG, Hoppe C, König J, Führer D, Moeller LC. Cell-Specific Transport and Thyroid Hormone Receptor Isoform Selectivity Account for Hepatocyte-Targeted Thyromimetic Action of MGL-3196. Int J Mol Sci. 2022;23(22):13714.
[6] Zhang YH, Xie R, Dai CS, et al. Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids. J Hepatol. 2025;82(2):189-202.
[7] Zhou M, Li C, Byrne FL, et al. Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease. Acta Physiol (Oxf). 2024;240(10):e14217.
MGL-3196是一种高选择性的口服甲状腺激素受体β(THRβ)激动剂,EC50为0.21μM[1]。THRβ是一种核受体,通过与甲状腺激素结合并调节基因表达,在代谢、生长和发育中发挥关键作用[2]。MGL-3196可用于研究非酒精性脂肪性肝炎(NASH)和心血管疾病[3][4]。
在体外实验中,用6μM的MGL-3196处理HEK-1B1细胞48小时,显著诱导了THRβ靶基因(如KLF9和PCK1)的表达,并增强了线粒体呼吸[5]。
在体内实验中,MGL-3196(3mg/kg/天;灌胃给药;持续8周)降低了喂食MASH饮食的SPF小鼠的肝脏重量,减少了循环中的甘油三酯和总胆固醇水平,并改善了脂肪肝和纤维化的组织学表现[6]。在由GAN饮食诱导的脂肪肝小鼠模型中,MGL-3196(1mg/kg/天; 口服给药;持续8周)显著降低了肝脏重量,改善了脂肪肝和小叶炎症的组织学评分,并降低了血浆胆固醇和丙氨酸转氨酶(ALT)水平[7]。
















